Filing Details

Accession Number:
0001209191-21-030350
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-05 13:00:00
Reporting Period:
2021-05-03
Accepted Time:
2021-05-05 16:40:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776938 Kevin Lee C/O Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-05-03 3,391 $14.00 258,125 No 4 M Direct
Ordinary Shares Disposition 2021-05-03 3,391 $32.16 254,734 No 4 S Direct
Ordinary Shares Acquisiton 2021-05-04 897 $14.00 255,631 No 4 M Direct
Ordinary Shares Disposition 2021-05-04 897 $32.03 254,734 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (right to buy) Disposition 2021-05-03 3,391 $0.00 3,391 $14.00
Ordinary Shares Stock Option (right to buy) Disposition 2021-05-04 897 $0.00 897 $14.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
422,761 2029-06-28 No 4 M Direct
421,864 2029-06-28 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.34 inclusive.
  4. This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.